Search results
Showing 46 to 60 of 64 results for feet
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
New draft guidance from NICE means thousands of people suffering with severe rheumatoid arthritis will have more medicines to choose from.
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It covers traumatic injuries to the spine but does not cover spinal injury caused by a disease. It aims to reduce death and disability by improving the quality of emergency and urgent care.
effective use of resources, and meets the needs of those with low risk diabetic feet while enabling the foot protection service to focus...
Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma (IPG539)
Evidence-based recommendations on radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma. This involves using pulses of radiofrequency heat energy to damage the nerve, with the aim of reducing pain.
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
Insertion of an epiretinal prosthesis for retinitis pigmentosa (IPG519)
Evidence-based recommendations on insertion of an epiretinal prosthesis for retinitis pigmentosa. This involves inserting an implant into the eye that receives data from a small camera on the person's glasses and then stimulates healthy cells in the retina to see basic images.
View recommendations for IPG519Show all sections
Evidence-based recommendations on insertion of a balloon device to disimpact an engaged fetal head before an emergency caesarean section.
The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)
NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .
This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS52Show all sections
Sections for QS52
- Quality statements
- Quality statement 1: Identification and assessment of peripheral arterial disease
- Quality statement 2: Comorbidity assessment
- Quality statement 3: Supervised exercise programmes
- Quality statement 4: Imaging
- Quality statement 5: Angioplasty for intermittent claudication
- About this quality standard
Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.